Erin Mangan

1.1k total citations
39 papers, 867 citations indexed

About

Erin Mangan is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Erin Mangan has authored 39 papers receiving a total of 867 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Rheumatology, 13 papers in Genetics and 13 papers in Hematology. Recurrent topics in Erin Mangan's work include Rheumatoid Arthritis Research and Therapies (29 papers), Systemic Lupus Erythematosus Research (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Erin Mangan is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (29 papers), Systemic Lupus Erythematosus Research (14 papers) and Chronic Lymphocytic Leukemia Research (13 papers). Erin Mangan collaborates with scholars based in United States, United Kingdom and France. Erin Mangan's co-authors include James W. Gober, Hubert van Hoogstraten, Neil M.H. Graham, Yong Lin, James A. Wingrove, Janet van Adelsberg, Gerd R Burmester, Jeffrey C. Edberg, Robert P. Kimberly and Eun Bong Lee and has published in prestigious journals such as Journal of Clinical Investigation, Genes & Development and The Journal of Immunology.

In The Last Decade

Erin Mangan

38 papers receiving 847 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Erin Mangan United States 15 397 247 216 212 180 39 867
Uri Arad Israel 14 231 0.6× 170 0.7× 78 0.4× 213 1.0× 75 0.4× 31 692
Qingyu Cheng Germany 14 308 0.8× 134 0.5× 92 0.4× 485 2.3× 65 0.4× 25 857
Diana Castaño Colombia 16 201 0.5× 322 1.3× 102 0.5× 750 3.5× 180 1.0× 32 1.2k
J. Arnoud Marquart Netherlands 15 221 0.6× 152 0.6× 348 1.6× 204 1.0× 82 0.5× 25 843
Christophe Picard France 21 87 0.2× 220 0.9× 326 1.5× 531 2.5× 58 0.3× 94 1.2k
D S Pisetsky United States 19 378 1.0× 224 0.9× 71 0.3× 692 3.3× 82 0.5× 30 996
Antonella Circolo United States 15 180 0.5× 156 0.6× 229 1.1× 704 3.3× 41 0.2× 32 1.0k
P Bird United Kingdom 17 140 0.4× 158 0.6× 218 1.0× 293 1.4× 72 0.4× 27 867
Rosario de Pablo Spain 20 136 0.3× 222 0.9× 114 0.5× 726 3.4× 345 1.9× 45 1.2k
Anja Geldhof Belgium 15 150 0.4× 121 0.5× 77 0.4× 607 2.9× 115 0.6× 47 945

Countries citing papers authored by Erin Mangan

Since Specialization
Citations

This map shows the geographic impact of Erin Mangan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erin Mangan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erin Mangan more than expected).

Fields of papers citing papers by Erin Mangan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erin Mangan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erin Mangan. The network helps show where Erin Mangan may publish in the future.

Co-authorship network of co-authors of Erin Mangan

This figure shows the co-authorship network connecting the top 25 collaborators of Erin Mangan. A scholar is included among the top collaborators of Erin Mangan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erin Mangan. Erin Mangan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wells, Alvin F., Janie Parrino, Erin Mangan, et al.. (2019). Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs. Rheumatology and Therapy. 6(3). 339–352. 25 indexed citations
3.
4.
Gossec, Laure, Vibeke Strand, Clare Proudfoot, et al.. (2019). Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. The Journal of Rheumatology. 46(10). 1259–1267. 10 indexed citations
5.
Strand, Vibeke, Laure Gossec, Clare Proudfoot, et al.. (2018). Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. Arthritis Research & Therapy. 20(1). 129–129. 26 indexed citations
6.
Goldman, Howard B., Matthias Oelke, Steven A. Kaplan, et al.. (2018). Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?. International Urogynecology Journal. 30(2). 239–244. 6 indexed citations
7.
Fleischmann, Roy, Alberto Spindler, Alan Kivitz, et al.. (2018). THU0217 Similar efficacy and safety of sarilumab 150 mg or 200 mg q2w regardless of primary (1°) or secondary (2°) failure with tnf inhibitors. Annals of the Rheumatic Diseases. 77. 328–328. 1 indexed citations
8.
Emery, Paul, et al.. (2018). 222 Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab. Lara D. Veeken. 57(suppl_3). 4 indexed citations
9.
Verschueren, Patrick, et al.. (2018). THU0215 Efficacy of sarilumab in patients with rheumatoid arthritis with and without previous response to tocilizumab. Annals of the Rheumatic Diseases. 77. 327–328. 5 indexed citations
10.
Strand, Vibeke, Matthew Reaney, Chieh-I Chen, et al.. (2017). Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. RMD Open. 3(1). e000416–e000416. 31 indexed citations
11.
12.
Heijde, Désirée van der, Janet van Adelsberg, Hubert van Hoogstraten, et al.. (2016). SAT0160 Clinical and Radiographic Outcomes after 2 Years of Sarilumab in Patients with Rheumatoid Arthritis. Annals of the Rheumatic Diseases. 75. 724–724. 5 indexed citations
13.
Strand, Vibeke, C. Chen, Pooja Mahajan, et al.. (2016). AB0251 Early Onset of Benefit by Patient-Reported Outcomes (PROs) with Sarilumab Treatment in RA. Annals of the Rheumatic Diseases. 75. 984–985. 1 indexed citations
14.
Darekar, Amanda, Martin Carlsson, Fady Ntanios, et al.. (2016). Development of a predictive model for urgency urinary incontinence. Contemporary Clinical Trials. 51. 44–49. 6 indexed citations
15.
Chapple, Christopher R., Tim Schneider, François Haab, et al.. (2014). Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double‐blind, placebo‐controlled EIGHT trial. British Journal of Urology. 114(3). 418–426. 28 indexed citations
16.
Weiss, Jeffrey P., et al.. (2013). 1962 AGE, GENDER AND NOCTURNAL URGENCY SEVERITY PREDICT RESPONSE TO ANTIMUSCARINIC TREATMENT. The Journal of Urology. 189(4S). 1 indexed citations
17.
Li, Xiaoli, Erin Mangan, Kaihong Su, et al.. (2012). The Unique Cytoplasmic Domain of Human FcγRIIIA Regulates Receptor-Mediated Function. The Journal of Immunology. 189(9). 4284–4294. 20 indexed citations
18.
Stein, Mary‐Pat, Jeffrey C. Edberg, Robert P. Kimberly, et al.. (2000). C-reactive protein binding to FcγRIIa on human monocytes and neutrophils is allele-specific. Journal of Clinical Investigation. 105(3). 369–376. 180 indexed citations
19.
Mangan, Erin, et al.. (1999). FlbT Couples Flagellum Assembly to Gene Expression in Caulobacter crescentus. Journal of Bacteriology. 181(19). 6160–6170. 47 indexed citations
20.
Gober, James W., et al.. (1995). Temporal and spatial regulation of fliP, an early flagellar gene of Caulobacter crescentus that is required for motility and normal cell division. Journal of Bacteriology. 177(13). 3656–3667. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uri Arad Breakdown of academic impact, for papers by Qingyu Cheng Breakdown of academic impact, for papers by Diana Castaño Breakdown of academic impact, for papers by J. Arnoud Marquart Breakdown of academic impact, for papers by Christophe Picard Breakdown of academic impact, for papers by D S Pisetsky Breakdown of academic impact, for papers by Antonella Circolo Breakdown of academic impact, for papers by P Bird Breakdown of academic impact, for papers by Rosario de Pablo Breakdown of academic impact, for papers by Anja Geldhof
Rankless by CCL
2026